Greenlee Pharmaceuticals has teamed up with AstraZeneta to advance its cardiovascular business

the evening of January 15, Greenlee Pharmaceuticals, a Hong Kong-listed company, announced that it would grant AstraZene the right to promote the group's first-line lipid management drug, Lipid Kang capsules, at Chinese mainland.
According to the announcement, several member companies of Greenlee Pharmaceutical Group have entered into an agreement with AstraZenecon under which AstraZeneta is responsible for the exclusive promotion of Lipidcon capsules in Chinese mainland, while Greenlee Pharmaceuticals continues to hold rights other than the rights to the promotion of the product's assets, sales rights, registration warrants, and all intellectual property rights.
addition, the two sides agreed that sales of hemolipid capsules at Chinese mainland will maintain double-digit compound annual growth rates over the next decade, well above the average growth rate of Chinese mainland in the market for the treatment of hyperlipidemia. Green leaf Pharmaceuticals said that with AstraZeneca's extensive experience in the cardiovascular sector, coupled with its excellent outreach capabilities and extensive business network, the group believes the appointment will strengthen and expand the market for lipid-health capsule products to benefit more patients with cardiovascular disease in China.
, in addition Chinese mainland, blood lipid capsules have been listed in Taiwan, Hong Kong, Singapore, Malaysia and other markets. AstraZene half of the company said it would take full advantage to further enrich and improve AstraZeneia's cardiovascular product line, complement its blood lipid abnormalities and atherosclerosis product line, promote the long-term development of AstraZeneia's China and cardiovascular businesses, and bring more quality treatment options to patients.
is currently recognized at home and abroad as a natural lipid drug brand. Based on the clear efficacy and safety of lipid reduction, it has been recommended as a first-line blood lipid management drug by the Guidelines for the Prevention and Control of Blood Lipid Abnormality in Chinese Adults (revised in 2016) and has been included in the latest edition of China's National Basic Medical Insurance and Industrial Injury Insurance Drug Catalog and the National Essential Drugs Catalog. (New Beijing News)